Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
2 Top Trends to Invest $2,000 in Ahead of the Crowd
02:45pm, Monday, 05'th Sep 2022 The Motley Fool
These two trends on the frontier of medicine could present lucrative opportunities for investment.
GSK (GSK) Gains As Market Dips: What You Should Know
09:45pm, Friday, 02'nd Sep 2022 Zacks Investment Research
GSK (GSK) closed at $31.85 in the latest trading session, marking a +0.5% move from the prior day.
Rolls-Royce, GSK, Tesla, Cineworld and Revolution Beauty top most-bought shares in August
02:45am, Friday, 02'nd Sep 2022
August's most popular shares for retail investors were dominated by apparent bargain hunting, with Rolls-Royce Holdings PLC (LSE:RR.), GSK PLC (LSE:GSK, NYSE:GSK) and Vodafone Group PLC (LSE:VOD) snap
This Overlooked Danger Could Tank Big Pharma Stocks
06:13pm, Thursday, 01'st Sep 2022
It started out relatively small, or as small as a recall of one of the first drugs to top $1 billion in annual sales can be. In September 2019, individual companies began recalling popular heartburn m
AstraZeneca wins injunction preventing former executive from joining GSK
10:55am, Thursday, 01'st Sep 2022
AstraZeneca PLC (LSE:AZN) has succeeded in stopping a former senior executive from joining rival GSK PLC (LSE:GSK, NYSE:GSK) via an injunction granted by a High Court judge. Having recently left A
Gilead (GILD) Outpaces Industry in Six Months: What Lies Ahead?
03:51pm, Tuesday, 30'th Aug 2022 Zacks Investment Research
Gilead (GILD) gains on the back of its strong HIV franchise and promising oncology business, which should propel growth further.
Pfizer (PFE) RSV Vaccine Found Effective in Older Adults
10:52am, Friday, 26'th Aug 2022 Zacks Investment Research
Based on the positive data from the phase III study on its RSV vaccine candidate, Pfizer plans to file a biologics license application (BLA) to the FDA in fall 2022.
3 Dependable Stocks With Dividend Yields Above 5%
02:53pm, Wednesday, 24'th Aug 2022 The Motley Fool
These three will pay you well while you wait for their shares to rebound.
3 Dependable Stocks With Dividend Yields Above 5%
10:53am, Wednesday, 24'th Aug 2022
These three will pay you well while you wait for their shares to rebound.
Haleon: World's Largest Over-The-Counter Business Looks Like A Buy Here
07:11pm, Monday, 22'nd Aug 2022 Investing.com
Gilead (GILD) Twice-Yearly HIV Treatment Gets EC Approval
03:57pm, Monday, 22'nd Aug 2022 Zacks Investment Research
Gilead (GILD) HIV treatment Sunlenca gets approved by the European Commission for adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-v
Is Hartford Multifactor Developed Markets exUS ETF (RODM) a Strong ETF Right Now?
10:20am, Monday, 22'nd Aug 2022 Zacks Investment Research
Smart Beta ETF report for RODM
Clouds Are Gathering (Again) For GSK
01:26am, Monday, 22'nd Aug 2022
GSK was having a turnaround year, with drugs pipeline strong and H1 results impressive. Zantac lawsuits are presenting a significant risk to investing in GSK.
The Rise and Fall of Novavax
12:45pm, Sunday, 21'st Aug 2022 The Motley Fool
The story of Novavax stock over the last few years would make an amazing book.
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
01:07pm, Friday, 19'th Aug 2022 Zacks Investment Research
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN)
